Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Rezolute, Inc.

NASDAQ: RZLT · Life Sciences · 7 alerts · CIK 1509261

Rezolute, Inc. stories on ALFA USA NewsRead the news →
Share price
$3.58Close, Nov 16
Market cap
$346M
Shares outstanding
96.72MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Rezolute, Inc. filings on SEC EDGAR ↗

5:12 PM ET 8-K
Business Update

Rezolute Business Update

Rezolute announced the completion of patient enrollment in its Phase 3 upLIFT study of ersodetug for the treatment of tumor hyperinsulinism. The company expects to release topline data from the 16-participant registrational study in mid-December 2026.

8:01 AM ET 8-K
Business Update

Rezolute Business Update

Rezolute announced that the FDA recommended a pre-BLA meeting for ersodetug in congenital hyperinsulinism (HI) following a review of Phase 3 sunRIZE data. Although the trial missed its primary and key secondary endpoints, the Agency encouraged the meeting as a precursor to a potential Biologics License Application (BLA) submission. The company is also awaiting Phase 3 upLIFT results in tumor HI this quarter to finalize its overall regulatory strategy.

Counterparty
FDA

“We appreciate FDA’s thorough review of the extensive body of data generated in sunRIZE and are encouraged by the Agency’s recognition that this data will require in-depth evaluation during a formal BLA review.”

Nevan Charles Elam, Chief Executive Officer and Founder of Rezolute

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.